Anlon Healthcare IPO: ₹121-Crore Pharma Gamble Starts on Grey Market Buzz

New Delhi, August 26, 2025 – Anlon Healthcare IPO, opening for subscription today, August 26, 2025, closing on August 29, registered initial market signals as positive with the issue commanding a 6% premium in the grey market over its price band of ₹86-₹91 per share. The ₹121-crore issue is a fresh issue of 1.33 crore equity shares and will list on September 3, reflecting the plan of the company to invest new money in growth and expansion.

Inside the IPO Details

Investors can offer in lots of 164 shares, which will be worth ₹14,924 at the top band, while the total issue size is ₹121 crore through a new issue of equity shares. Interactive Financial Services Ltd has been appointed as the lead manager for the issue. Investor key dates are August 29 confirmation of UPI mandate by 5 PM, September 1 finalization of allotment, September 2 initiation of refund and crediting of demat share, and the listing of stock on both the NSE and BSE on September 3, 2025.

Aggressive Growth and Strategic Initiatives

Investor sentiment has been driven higher by the strong financials of Anlon. Revenues nearly doubled to ₹120.5 crore from ₹66.7 crore in FY25, with net profit rising to ₹20.5 crore. The proceeds of the issue will be used to grow capacity, repay debt, and finance working capital requirements critical to its capital-intensive business model.

The allocation pattern also has heightened interest: 75% of the issue shall be allocated to institutional buyers, 15% to non-institutional buyers, and a paltry 10% to retail participants. With a lower retail share, allotment competition is sure to be intense, aligning with the subscription mania.

Opportunity with Risks Attached

Anlon Healthcare, established in 2013, makes Active Pharmaceutical Ingredients (APIs), intermediates, and nutraceuticals from a single ISO and WHO-GMP certified facility in Rajkot. Its business aligns with India’s growing push towards indigenous pharma production and reduced import reliance, giving it a friendly long-term backdrop.

However, investors must factor in possible risks. The company is greatly dependent on one facility, which subjects it to interruption of operations. Customer concentration is extreme with a significant percentage of revenues coming from a limited number of sources. Regulation remains a key consideration, and prior temporary shutdowns can be an indicator of sensitivity towards compliance.

For shareholders, the IPO offers a wager on the expanding pharma and API sector, supported by some astounding growth rates. But the real test lies well beyond listing whether Anlon will be able to diversify, ramp up sustainably, and insulate itself against dependence risks in a competitive market.

Established in 2013, Anlon Healthcare began commercial operations in 2017 and operates a single manufacturing facility in Rajkot, Gujarat, certified by ISO 9001:2015, GMP, and WHO-GMP. The company produces Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, and nutraceutical compounds, catering to both domestic markets and selective exports.

Disclaimer:  At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations